Merck Discontinues Nemtabrutinib Program Following Review Of Phase 3 Trial Data
Merck (MRK) is halting development of nemtabrutinib, an experimental BTK inhibitor, after a Phase 3 trial review suggested its risks may outweigh benefits. The decision impacts multiple studies in the BELLWAVE program. Merck will notify patients and investigators, and continue analyzing data. The stock closed at $143.37, down 0.75%.
How this was made

The 30-second read
Why it matters
The announcement is the first public disclosure of the trial discontinuation, making it a primary corporate development with material implications for Merck's oncology pipeline.
Market read
The news is likely to trigger a modest sell‑off in MRK shares and could affect sentiment toward other BTK inhibitor developers.
What to watch
The company emphasized continued commitment to its overall hematology pipeline, which may mitigate the setback.
Background
Merck (MRK) halted development of nemtabrutinib, a non‑covalent BTK inhibitor for CLL/SLL, after a Phase 3 trial failed to show sufficient benefit.
Ticker impact
Merck announced the discontinuation of its nemtabrutinib Phase 3 program after a Data Monitoring Committee review.
likely downward pressure as investors reassess hematology pipeline prospects
Trial discontinuation removes a potential future revenue source and signals higher risk for the blood‑cancer franchise.
Market effects
May dampen sentiment for the broader oncology/hematology sector as investors re‑evaluate other BTK inhibitor programs.
US biotech stocks could see modest pullback, especially peers with similar pipelines.
Limited to pharma/biotech investors; no broad market effect.
Counterpoint
If Merck reallocates resources to more promising assets, the long‑term impact could be neutral or positive.
Key entities
- companyMerck & Co., Inc.
US‑listed pharmaceutical company (ticker MRK) that discontinued the nemtabrutinib program.
- drugNemtabrutinib
Investigational BTK inhibitor being evaluated for blood cancers.



